AlzeCure Pharma

AlzeCure Pharma (Stockholm: ALZCUR)

Currency in SEK

Last close As at 06/02/2023

SEK5.28

▲ −0.18 (−3.30%)

Market capitalisation

SEK268m

Overview
Price performance
Financials
Research
Thematics

Edison Investment Research is terminating coverage on AlzeCure Pharma. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Latest Insights

Healthcare

30.05.22

AlzeCure Pharma — Progress on all fronts and evolving into Phase II

Healthcare

09.02.22

AlzeCure Pharma: Edison Open House Healthcare 2022

Healthcare

05.01.22

AlzeCure Pharma — Evolving into a mid-stage biotech

Healthcare

27.08.21

AlzeCure Pharma — ACD856: Phase I progressing after SAD data

Visit Website

Sector

Healthcare

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	40.1	79.6	(32.4)
Relative	51.9	94.1	(9.4)
52 week high/low	SEK7.6/SEK2.2

Financials

AlzeCure Pharma is a clinical-stage biotech company based in Sweden focused on developing innovative, small molecule drugs for the treatment of Alzheimer’s disease (symptomatic as well as disease modifying) and pain (neuropathic and osteoarthritic).